Safety and efficacy of optimized tandem CD19/CD20 CAR-engineered T cells in patients with relapsed/refractory non-Hodgkin lymphoma.

被引：0
|
作者：
Zhang, Yajing [1 ]
机构：
[1] Chinese Peoples Liberat Army Gen Hosp, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
基金：
中国国家自然科学基金;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3034
引用
收藏
页数：1
相关论文
共 50 条
  • [31] iPSC-derived CD19 CAR NK cells for relapsed or refractory lymphoma
    Shapiro, Roman M.
    Romee, Rizwan
    LANCET, 2025, 405 (10473): : 98 - 99
  • [32] A phase 1 study of AT101, a novel anti-CD19 CAR-T cell therapy targeting a membrane-proximal epitope of CD19, in patients with relapsed or refractory B cell non-Hodgkin lymphoma.
    Yoon, Dok Hyun
    Cho, Hyungwoo
    Jo, Jae-Cheol
    Jeong, Seong Hyun
    Oh, Sung Yong
    Kim, Ki Hyun
    Cui, LeiGuang
    Lee, Tae-Bum
    Hwang, In-Sik
    Lee, Young-Ha
    Lee, Yong-Jun
    Kim, Jong-Hoon
    Ruella, Marco
    Lee, Jong-Seo
    Chung, Junho
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [33] CD19 Intron Retention Is Mechanism of CAR-T Treatment Resistance in Non-Hodgkin Lymphoma
    Noble, Jerald
    Locke, Frederick L.
    Savid-Frontera, Constanza
    Jain, Michael D.
    Turner, Joel G.
    Miranda, Julieta Abraham
    Madanayake, Thushara W.
    Naderinezhad, Samira
    Corallo, Salvatore
    Menges, Meghan
    Reid, Kayla
    Robinson, Timothy J.
    BLOOD, 2023, 142
  • [34] Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma
    Liu, Meijing
    Deng, Haobin
    Mu, Juan
    Li, Qing
    Pu, Yedi
    Jiang, Yili
    Deng, Qi
    Qian, Zhengzi
    CANCER SCIENCE, 2021, 112 (07) : 2642 - 2651
  • [35] Safety and efficacy of a novel anti-CD20 chimeric antigen receptor (CAR)-T cell therapy in relapsed/refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL) patients after failing CD19 CAR-T therapy.
    Liang, Aibin
    Ye, Shiguang
    Li, Ping
    Huang, Jiaqi
    Zhu, Shigui
    Yao, Xin
    Zhou, Lili
    Xu, Yangyang
    Zhu, Judy
    Zheng, Chengxiao
    Chen, Shiyi
    Lan, Liping
    Lv, Xiaoteng
    Wei, Yutian
    Humphries, Michael
    Yao, Yihong
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [36] Comparative evaluation of peripheral blood T cells and resultant engineered anti-CD19 CAR T cell products from relapsed/refractory non-Hodgkin's lymphoma (NHL) patients
    Langer, Timothy
    Lowe, Emily
    Perez, Arianne
    Rosenberg, Steven
    Feldman, Steven A.
    Lu, Lily
    Rossi, John M.
    Chang, Edmund
    Sherman, Marika
    Better, Marc
    Kochenderfer, James N.
    Bot, Adrian
    CANCER RESEARCH, 2016, 76
  • [37] Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B-cell non-Hodgkin lymphoma
    Bender, Brendan
    Li, Chi-Chung
    Marchand, Mathilde
    Turner, David C.
    Li, Feifei
    Vadhavkar, Shweta
    Wang, Bei
    Deng, Rong
    Lu, James
    Jin, Jin
    Li, Chunze
    Yin, Shen
    Wei, Michael
    Chanu, Pascal
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (06):
  • [38] Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease
    Giles, FJ
    Vose, JM
    Do, KA
    Johnson, MM
    Manshouri, T
    Bociek, G
    Bierman, PJ
    O'Brien, SM
    Keating, MJ
    Kantarjian, HM
    Armitage, JO
    Albitar, M
    BRITISH JOURNAL OF HAEMATOLOGY, 2003, 123 (05) : 850 - 857
  • [39] Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
    Lihong An
    Yuehui Lin
    Biping Deng
    Zhichao Yin
    Defeng Zhao
    Zhuojun Ling
    Tong Wu
    Yongqiang Zhao
    Alex H. Chang
    Chunrong Tong
    Shuangyou Liu
    BMC Cancer, 22
  • [40] Rituximab in the management of non-Hodgkin lymphoma. expressing CD20 (Egyptian single institution experience)
    Azim, HA
    Azim, HA
    Moneim, DA
    Kamal, NS
    ANNALS OF ONCOLOGY, 2005, 16 : 303 - 303
12345